Focus on Janus Kinase Inhibitors in Rheumatoid Arthritis

In this downloadable slideset, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.14 MB
Released: August 1, 2016

Acknowledgements

Supported by an educational grant from
Lilly USA, LLC

Related Content

Expert commentary on real-world and trial data on treating RA after failing biologic and targeted small-molecule DMARDs, from EULAR 2020 by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 27, 2020 Expired: August 26, 2021

Expert commentary on key studies in RA comorbidities from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

EULAR 2020 on SELECT-CHOICE: upadacitinib vs abatacept for active rheumatoid arthritis with prior inadequate response or intolerance to bDMARDs as reported by CCO

Released: August 17, 2020

New from EULAR 2020, Clinical Care Options (CCO): adults with immune-mediated inflammatory disease report biologic-associated fatigue in Dutch Biologic Monitor

Released: August 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue